Item 8.01 Other Events.
On November 6, 2012, MEI Pharma, Inc. (the "Company"), announced that
preliminary data from a pilot Phase II clinical trial of the Company's
investigational oral histone deacetylase (HDAC) inhibitor, Pracinostat, in
combination with azacitidine in patients with advanced myelodysplastic syndrome
(MDS) has been accepted for poster presentation at the American Society of
Hematology Annual Meeting on December 10, 2012. An abstract of the presentation,
entitled "Very high rates of clinical and cytogenetic response with the
combination of the histone deacetylase inhibitor Pracinostat (SB939) and
5-azacitidine in high-risk myelodysplastic syndrome," was submitted by
Dr. Quintás-Cardama and Dr. Garcia-Manero of the MD Anderson Cancer Center.
Based on these data and the Company's planned equity financing announced on
November 5, 2012, the Company expects to be in a position to initiate a
randomized Phase II trial of Pracinostat in combination with azacitidine in
patients with MDS by the second quarter of 2013.
Add
MEIP to Portfolio
Set Alert
Email to a
Friend